Severe asthma is a specific subset of asthma that remains uncontrolled despite the highest levels of standard treatment, or that requires those high-level treatments just to stay under control. It affects roughly 5 to 10% of all people with asthma. While any asthma can feel serious during a flare-up, severe asthma is a distinct clinical category with different biology, different risks, and different treatment options than the milder forms most people are familiar with.
How Severe Asthma Differs From Other Asthma
Not all poorly controlled asthma qualifies as severe. Doctors draw an important line between “difficult-to-treat” asthma and truly severe asthma. Difficult-to-treat asthma looks uncontrolled, but the real problem is something fixable: a patient isn’t using their inhaler correctly, they’re missing doses, they’re exposed to an allergen they haven’t identified, or a condition like acid reflux or chronic sinus disease is making things worse. Once those factors are addressed, the asthma often improves.
Severe asthma is what’s left after all of those fixable problems have been ruled out. It’s defined by the European Respiratory Society and American Thoracic Society as asthma that remains uncontrolled despite high-dose combination inhaler therapy (the highest treatment steps, 4 or 5, on international guidelines), or asthma that requires those treatments, sometimes including long-term oral steroids, just to maintain partial control. In a large general population study, about 9.5% of adults with asthma met the criteria for the severe category, translating to roughly 1 in 100 adults overall.
What Severe Asthma Feels Like Day to Day
People with severe asthma experience the same core symptoms as other asthma patients: wheezing, chest tightness, shortness of breath, and coughing. The difference is in frequency, intensity, and how little relief standard treatments provide. Symptoms often intrude on sleep, limit physical activity, and force changes to work or social life. One widely used screening tool, the Asthma Control Test, scores asthma control on a scale from 5 (worst) to 25 (best). A score below 16 signals uncontrolled asthma, and many people with severe asthma live in that range even while taking multiple medications.
Flare-ups, or exacerbations, are a defining burden. In a U.S. study of nearly 1,900 patients with severe asthma, more than half experienced at least one exacerbation over a year, and about 12% were hospitalized. Of all exacerbations recorded, 15% required a hospital stay and another 9% involved an emergency department visit. These episodes aren’t just scary in the moment. They accelerate long-term lung damage and carry real mortality risk.
The Biology Behind It
Severe asthma isn’t one disease. It comes in distinct biological subtypes, and identifying which subtype a person has is now central to choosing the right treatment.
The most common subtype is called “Type 2 high” (or T2-high). In this form, the immune system overproduces specific inflammatory signals that drive a buildup of a white blood cell type called eosinophils in the airways. This eosinophilic inflammation causes swelling, excess mucus, and airway narrowing. It can be allergic (triggered by things like dust mites or pet dander, with elevated IgE antibodies in the blood) or non-allergic. Doctors identify T2-high asthma through blood eosinophil counts, IgE levels, and exhaled nitric oxide, a breath test that reflects airway inflammation.
The other major subtype, “Type 2 low” (T2-low), is less well understood. It tends to involve more structural remodeling of the airways, sometimes with neutrophilic inflammation rather than eosinophilic. It responds poorly to standard anti-inflammatory treatments, and there are currently no reliable biomarkers to identify it in a clinic visit. This subtype is an active area of investigation, and treatment options are more limited.
Conditions That Often Come With It
Severe asthma rarely travels alone. Data from the Swiss Severe Asthma Registry found that 55% of patients had allergies, 48% had chronic sinus inflammation, 35% had nasal polyps, 29% had gastroesophageal reflux disease (GERD), 27% were living with obesity, and about 10% had depression. These aren’t just coincidences. Each of these conditions can worsen airway inflammation, trigger more frequent flare-ups, or reduce the effectiveness of asthma medications.
COPD (chronic obstructive pulmonary disease) overlapped in about 12% of patients, and this combination is particularly difficult to manage. Depression, present in about 1 in 10 patients, has a measurable negative impact on asthma control and quality of life, likely because it makes it harder to keep up with complex treatment regimens and avoid triggers.
How Severe Asthma Is Treated
Treatment starts with optimizing the basics. Patients typically use a combination inhaler containing a corticosteroid and a long-acting bronchodilator, taken twice daily. Some treatment approaches use a single inhaler for both daily maintenance and quick relief during symptoms, which has been shown to reduce severe flare-ups compared to carrying a separate rescue inhaler. If that combination isn’t enough, a third type of inhaler (a long-acting muscarinic antagonist) can be added.
When high-dose inhalers still aren’t enough, the next step is biologic therapy. These are injectable medications, typically given every few weeks, that target specific molecules driving the inflammation. Six biologics are currently available for severe asthma, each matched to a different part of the immune pathway:
- Omalizumab blocks IgE, the antibody involved in allergic reactions, preventing it from activating immune cells that release histamine and other inflammatory chemicals.
- Mepolizumab and reslizumab block IL-5, a signaling molecule that recruits and sustains eosinophils in the airways.
- Benralizumab targets the IL-5 receptor directly, sitting on eosinophils and basophils and effectively clearing them from the airway.
- Dupilumab blocks the receptor for both IL-4 and IL-13, two signals that drive T2-high inflammation, mucus production, and airway remodeling.
- Tezepelumab targets TSLP, a molecule released by airway cells at the very start of the inflammatory cascade. Because it acts upstream, it can help patients with both T2-high and some T2-low profiles.
Choosing the right biologic depends on a patient’s biomarker profile: blood eosinophil count, IgE levels, and exhaled nitric oxide results all help guide the decision. The goal is to reduce exacerbations, lower or eliminate the need for oral steroids, and improve daily symptom control.
Bronchial Thermoplasty
For patients whose severe asthma doesn’t respond adequately to any available medication, bronchial thermoplasty is a procedure option. A pulmonologist threads a thin, flexible device into the airways and applies controlled heat to the smooth muscle lining the bronchial walls. This muscle is what contracts and narrows the airway during an asthma attack. The heat shrinks the muscle tissue; one study found a 53% reduction in airway smooth muscle mass after the procedure. It’s done in three separate sessions, each targeting a different section of the lungs, and is reserved for cases where quality of life remains significantly impaired despite full medical therapy.
Long-Term Risks and Mortality
Severe asthma carries meaningfully higher long-term risks than milder forms. A large Nordic study (the NORDSTAR cohort) followed patients for 20 years and found that 34% of those with severe asthma had died by the end of follow-up, compared to 20% of those with mild-to-moderate asthma. The overall risk of death from any cause was roughly twice as high in the severe group. The risk of dying specifically from asthma was three times higher.
Much of the excess mortality was driven by respiratory disease, which accounted for a cumulative death rate of 12.6% in the severe group versus 3.3% in the mild-to-moderate group. Long-term oral corticosteroid use, common in severe asthma, contributed significantly to these risks. When researchers adjusted for steroid use, the mortality gap narrowed considerably, underscoring how much damage these medications can cause over years, even as they control symptoms. This is a key reason why modern treatment strategies prioritize biologics as a way to get patients off oral steroids.
Why the Subtype Matters
If you’ve been told you have severe asthma, the single most important next step is identifying your biological subtype. The difference between T2-high and T2-low asthma isn’t academic. It determines whether any of the six available biologics are likely to help you, and which one is the best match. A patient with high blood eosinophils and elevated exhaled nitric oxide has multiple effective biologic options. A patient with a T2-low profile currently has fewer targeted choices, though tezepelumab may offer some benefit regardless of T2 status because it acts earlier in the inflammatory chain.
Getting the subtype wrong, or never identifying it at all, means years of relying on oral steroids and rescue inhalers that control symptoms at a steep cost to bone density, blood sugar, weight, and cardiovascular health. Phenotyping through blood tests and breath analysis is straightforward, widely available, and changes the trajectory of the disease for many patients.